4-tolyl isocyanate : An isocyanate comprising a benzene core with isocyanato and methyl substituents para to each other. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 69325 |
| CHEBI ID | 53732 |
| SCHEMBL ID | 93286 |
| MeSH ID | M0085225 |
| Synonym |
|---|
| STL299671 |
| TMI , |
| benzene, 1-isocyanato-4-methyl- |
| isocyanic acid, p-tolyl ester |
| p-tmi |
| 4-methylphenyl isocyanate |
| p-toluene isocyanate |
| 4-tolyl isocyanate |
| ai3-28256 |
| 1-isocyanato-4-methylbenzene |
| p-isocyanatotoluene |
| p-tolyl isocyanate , |
| p-methylphenyl isocyanate |
| einecs 210-743-4 |
| 4-isocyanatotoluene |
| 622-58-2 |
| PTI , |
| p-tolyl isocyanate, 99% |
| AKOS000202531 |
| CHEBI:53732 , |
| para-tolyl monoisocyanate |
| p-tolylmonoisocyanate |
| 4-tol-nco |
| isocyanic acid p-tolyl ester |
| T0321 |
| para-tolyl isocyanate |
| tolyl mono-isocyanate |
| p-tolylisocyanate |
| 1-isocyanato-4-methyl-benzene |
| A833679 |
| ec 210-743-4 |
| unii-btr9s4n53v |
| btr9s4n53v , |
| 374675-64-6 |
| A823680 |
| FT-0618818 |
| EPITOPE ID:116221 |
| 4'-methyl-2-cyano-biphenyl |
| SCHEMBL93286 |
| para-tolylisocyanate |
| paramethylphenylisocyanate |
| 4-methyl phenyl isocyanate |
| p-tolyl-isocyanate |
| p-methylphenylisocyanate |
| 4-methyl-phenyl-isocyanate |
| 4-methyphenylisocyanate |
| 4-methylphenylisocyanate |
| 4-tolylisocyanate |
| paratoluylisocyanate |
| DTXSID2060755 |
| 4-isocyanato-1-methylbenzene |
| 4-methylphenyl diiodomethylsulfone |
| Q-200500 |
| F2190-0548 |
| p-tolyl isocyanat |
| mfcd00002029 |
| Q26840811 |
| MS-20631 |
| 1-isocyanato-4-methylbenzene; 4-isocyanatotoluene |
| D92322 |
| EN300-20864 |
| Role | Description |
|---|---|
| hapten | Any substance capable of eliciting an immune response only when attached to a large carrier such as a protein. Examples include dinitrophenols; oligosaccharides; peptides; and heavy metals. |
| allergen | A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| isocyanates | Organonitrogen compounds that are derivatives of isocyanic acid; compounds containing the isocyanate functional group -N=C=O (as opposed to the cyanate group, -O-C#N). |
| toluenes | Any member of the class of benzenes that is a substituted benzene in which the substituents include one (and only one) methyl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (88.89) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.02) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 2 (22.22%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||